

APPLIED DNA SCIENCES INC  
Form 8-K/A  
December 11, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K/A**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): December 6, 2018

**Applied DNA Sciences, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

**001-36745**

**59-2262718**

(State or other jurisdiction  
of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

**50 Health Sciences Drive**

**Stony Brook, New York 11790**

(Address of principal executive offices; zip code)

Registrant's telephone number, including area code:

**631-240-8800**

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



### **Explanatory Note**

As previously reported in a Current Report on Form 8-K filed on December 6, 2018 (the “Form 8-K”), Applied DNA Sciences, Inc. (the “Company”), announced that its wholly-owned subsidiary, LineaRx, Inc. was providing a presentation to the investment community via an analyst day webinar held on December 6, 2018 at 12pm EST. A copy of the presentation materials to be used by Applied DNA Sciences, Inc. during its presentation was furnished as Exhibit 99.1 to the Form 8-K.

The Amendment No. 1 to Form 8-K (the “Amendment”) is being filed solely to supplement the exhibits filed with the Form 8-K with the transcript of the presentation held via webinar on December 6, 2018.

### **Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.2 Transcript from webinar presentation on December 6, 2018 (furnished with the Commission as part of this Form 8-K)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 11, 2018 APPLIED DNA SCIENCES,  
INC.

By: /s/ James A. Hayward  
Name: James A. Hayward  
Title: Chief Executive Officer